Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Rebecca Zisser / Axios

In many ways, there was the world before humans had their genome sequence in hand — and the world after. Craig Venter was the mastermind of the private effort to map the genome in the late 1990s. Since then, he's tried to deliver on the promises that came with it, launching companies and ruffling feathers along the way.

I spoke with Venter on Tuesday in Washington, D.C. Here are some lightly edited highlights from our conversation:

How the DBC works:

It's the interconvertibility of going from the four bases of the genetic code, to ones and zeroes in the computer. You can send those ones and zeroes as electromagnetic waves then convert them back into the genetic code. The DBC actually receives the digital message as completely autonomous, literally writes out the genetic code chemically, and assembles the pieces into larger pieces.
If the end point is a protein, such as insulin, it makes the protein. If it's a vaccine, such as the flu vaccine, then it makes it automatically. It can make a phage, it can make viruses, and in theory it could make the entire bacterial genome — that would just have to be booted up. It means that because all life is DNA- based, we can send the least formula for all life digitally anywhere in the universe.

The most exciting applications for DBC:

The one that we'd like to see implemented would be totally eliminating pandemics because we can send a new vaccine around the world in a fraction of a second. If there were multiple of these receivers, it would be very easy to very quickly distribute the vaccine, which isn't the history of what's happened with vaccines.
I think there's far more exciting things. If we're really going to go to Mars and other places, it's the way to send new organisms for manufacturing there. It's a way to send a new phage for treating disease, new proteins, antibiotics, etc.

The DBC's biggest challenge:

It's a dual-use technology, so the robot we've released has all kinds of security mechanisms built in so you can't go and make small pox virus with it. That's because we control remotely the DNA synthesis portion of it and the robot just does the assembly in the latter stages. If people could just buy the DBC that does all these things, it's infinitely programmable and would make it very easy for people to make pathogenic viruses and organisms. It's not a technology problem, it's a security problem. How do you control the technology? The best way to do it is to have good countermeasures, which means more effective antibiotics, antivirals, vaccines, and it just becomes the same vicious cycle, whether it's deliberate bio-terrorism or a new emerging infection.

If this will cheapen life:

Hopefully some life forms like microbial ones for manufacturing would become common, not cheap. I spent a year in Vietnam, life became very cheap there, so that has very different context for me.
Thus far, we only have my institute and my company, Synthetic Genomics, that have truly made a synthetic cell. It's a little early on — and they weren't cheap.
If DNA synthesis and writing the genetic code becomes really faster and cheaper, which it will, it increases the odds that it will be widely used for developing new things.

If the U.S. is losing scientists:

It's not so much losing them as we're not letting them come in. That's a huge problem and a huge problem with interns and residents as well. They're being blocked from mentoring and foreign individuals are a huge source of talent in the U.S. in medicine and science.
Because we have so many sources of funding, the fact that the government is pretty incompetent...is overcome by this incredible investment community we have that creates a source of money that doesn't exist in any other country...It's all the money that is given back by people who've made it and a lot of those same people do a lot of investment on new, wild ideas, so we have ways around the sluggish, incompetence of government programs.

Thoughts about the recent gene editing of embyros:

It depends on whether they're going to be taken to term or not. We sort of decided globally at the end of World War II that the ethic was not to do human experimentation just randomly. People are editing with CRISPR and other things without proving that there's no off target effects, which there are with CRISPR.
Nobody to my knowledge has sequenced the human genome on anything they're editing. They're just assuming they're not getting off target effects. They wouldn't know what the mutations meant anyway. Germline editing is something there should be a lot of discussion on before it's ever decided to start down that slippery slope.
Polls in the past have shown that most young couples would want to use it just for superficial trait selection for their children — muscle types, hair color, eye color, things like that versus lethal disease elimination...[If manic depression is] treated as a disease that we want to eliminate from the population using CRISPR, basically the history of creativity and of humans has all been done by people with some degree of manic depression, probably including myself.
It depends what you define as a disease and if you want a population of homogenous clones. That's not a good direction for humanity.

Go deeper

America's child care sticker shock

Illustration: Sarah Grillo/Axios

Parents looking to return to the job market may find child care options have gotten pricier — and that's if they can enroll their kids at all.

Why it matters: The fate of the recovery partially relies on the return of parents who left the workforce to care for their children.

Biden's major border shake-up

A migrant family waits to be taken to a Border Patrol processing facility after crossing the Rio Grande River. Photo: Brandon Bell/Getty Images

Vice President Kamala Harris' trip to the border on Friday will play out amid the Biden administration widening shake-up of U.S. border policy and leadership.

Driving the news: Rep. Henry Cuellar (D-Tex.) tells Axios that he's been advised by a border official that as soon as mid-July the Biden administration will end all use of Title 42, a Trump-era policy citing coronavirus as rationale to block migrants at the border.

DeSantis signs law requiring college faculty, students to take surveys on beliefs

Florida Gov. Ron DeSantis. Photo: Joe Raedle/Getty Images

Florida Gov. Ron DeSantis (R) signed legislation requiring state colleges and universities to annually survey their students, faculty and staff about their beliefs to ensure "viewpoint diversity and intellectual freedom."

Why it matters: The legislation doesn't specify for what the survey results will be used, but at a press conference on Tuesday DeSantis said that schools found to be "indoctrinating" students aren't "worth tax dollars" and are "not something we’re going to be supporting going forward."